<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	>

<channel>
	<title>Mesothelioma Journal Articles</title>
	<atom:link href="http://www.mesothelioma-line.com/articles/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.mesothelioma-line.com/articles</link>
	<description>Journal Articles on Mesothelioma: Cancer Information for Patients and Families</description>
	<pubDate>Tue, 26 Aug 2008 20:22:39 +0000</pubDate>
	<generator>http://wordpress.org/?v=2.6</generator>
	<language>en</language>
			<item>
		<title>Primary malignant mesothelioma developed in liver</title>
		<link>http://www.mesothelioma-line.com/articles/2008/08/19/primary-malignant-mesothelioma-developed-in-liver/</link>
		<comments>http://www.mesothelioma-line.com/articles/2008/08/19/primary-malignant-mesothelioma-developed-in-liver/#comments</comments>
		<pubDate>Tue, 19 Aug 2008 20:19:55 +0000</pubDate>
		<dc:creator>Administrator</dc:creator>
		
		<category><![CDATA[Case Study]]></category>

		<category><![CDATA[Diagnosis &#038; Differentiation]]></category>

		<category><![CDATA[Epithelioid]]></category>

		<category><![CDATA[Full Archive]]></category>

		<category><![CDATA[Immunohistochemistry or IHC]]></category>

		<category><![CDATA[Radiofrequency Ablation]]></category>

		<category><![CDATA[Surgery]]></category>

		<category><![CDATA[Treatment]]></category>

		<category><![CDATA[Type of Assessment:]]></category>

		<category><![CDATA[Type of Mesothelioma:]]></category>

		<guid isPermaLink="false">http://www.mesothelioma-line.com/articles/?p=1318</guid>
		<description><![CDATA[Hepato-gastroenterology. 2008 May-Jun;55(84):1081-4. [Link]
Kim DS, Lee SG, Jun SY, Kim KW, Ha TY, Kim KK.
Division of Transplantation and Hepatobiliary Surgery, Department of Surgery, University of Cincinnati, Cincinnati, OH, USA.
Abstract
 The following reports a rare case of primary localized malignant mesothelioma of the liver. A 53-year-old man with no history of exposure to asbestos was admitted [...]]]></description>
			<content:encoded><![CDATA[<p><em>Hepato-gastroenterology</em>. 2008 May-Jun;55(84):1081-4. [<a href="http://www.ncbi.nlm.nih.gov/pubmed/18705333?dopt=AbstractPlus" target="_blank">Link</a>]</p>
<p><strong>Kim DS, Lee SG, Jun SY, Kim KW, Ha TY, Kim KK.</strong></p>
<p>Division of Transplantation and Hepatobiliary Surgery, Department of Surgery, University of Cincinnati, Cincinnati, OH, USA.</p>
<h3 class="abstract">Abstract</h3>
<p> The following reports a rare case of primary localized malignant mesothelioma of the liver. A 53-year-old man with no history of exposure to asbestos was admitted to our department for evaluation of incidentally detected liver mass. Computed tomography and hepatic angiogram showed a tumor at the dome of the liver, which was fed mainly through the inferior phrenic artery. The mass was resected, including a portion of the diaphragm. Microscopically, the tumor was composed of cord-like or trabecular arrangements of epithelioid cells having abundant eosinophilic cytoplasm and prominent nucleoli. Immunohistochemically, the tumor cells were strongly positive for calretinin and cytokeratin 5 and negative for hepatocyte markers. These findings were consistent with our diagnosis of epithelioid mesothelioma. A local recurrence was noted 15 months after surgery, which was treated by radiofrequency ablation. At 23 months after initial surgery, locally recurrent masses with direct invasion of the diaphragm and a solitary intrahepatic metastasis were noted, which was treated by partial excision of the diaphragm with intraoperative RFA after transarterial chemoembolization.</p>
<h3 class="glossary">Glossary</h3><dl class="glossary"><dt>recurrence</dt><dd> cancer that has come back after treatment. Local recurrence is when the cancer comes back at the same place as the original cancer. Regional recurrence is when the cancer appears in the lymph nodes near the first site. Distant recurrence is when it appears in organs or tissues (such as the lungs, liver, bone marrow, or brain) farther from the original site than the regional lymph nodes. Metastasis means that the disease has recurred at a distant site.</dd><dt>metastasis</dt><dd><span class="pronunciation">(meh-tas-teh-sis)</span><!--StartFragment --> the spread of cancer cells to distant areas of the body by way of the lymph system or bloodstream. </dd><dt>diagnosis</dt><dd> identifying a disease by its signs or symptoms, and by using imaging procedures and laboratory findings. The earlier a diagnosis of cancer is made, the better the chance for long-term survival.</dd><dt>tumor</dt><dd> an abnormal lump or mass of tissue. Tumors can be benign (not cancerous) or malignant (cancerous).</dd><dt>mesothelioma</dt><dd>a tumor derived from mesothelial tissue, such as the peritoneum (lining the abdomen) or pleura (lining the lungs). More on <a href="http://www.mesotheliomacenter.org/">mesothelioma</a>. </dd></dl>]]></content:encoded>
			<wfw:commentRss>http://www.mesothelioma-line.com/articles/2008/08/19/primary-malignant-mesothelioma-developed-in-liver/feed/</wfw:commentRss>
		</item>
		<item>
		<title>Rectus abdominis muscle resection for abdominal wall recurrence of mucinous adenocarcinoma or peritoneal mesothelioma</title>
		<link>http://www.mesothelioma-line.com/articles/2008/08/19/rectus-abdominis-muscle-resection-for-abdominal-wall-recurrence-of-mucinous-adenocarcinoma-or-peritoneal-mesothelioma/</link>
		<comments>http://www.mesothelioma-line.com/articles/2008/08/19/rectus-abdominis-muscle-resection-for-abdominal-wall-recurrence-of-mucinous-adenocarcinoma-or-peritoneal-mesothelioma/#comments</comments>
		<pubDate>Tue, 19 Aug 2008 20:15:51 +0000</pubDate>
		<dc:creator>Administrator</dc:creator>
		
		<category><![CDATA[Diagnosis &#038; Differentiation]]></category>

		<category><![CDATA[Full Archive]]></category>

		<category><![CDATA[Peritoneal (Abdominal Mesothelioma)]]></category>

		<category><![CDATA[Type of Assessment:]]></category>

		<category><![CDATA[Type of Mesothelioma:]]></category>

		<category><![CDATA[laparoscopy]]></category>

		<guid isPermaLink="false">http://www.mesothelioma-line.com/articles/?p=1316</guid>
		<description><![CDATA[Tumori. 2008 May-Jun;94(3):309-13.[Link]
  Yan T, Sugarbaker P.
 Peritoneal Surface Malignancy Program, Washington Cancer Institute, Washington Hospital Center, Washington, DC 20010, USA.
Abstract
 Aims and Background: Diagnostic technologies which penetrate the abdominal wall in an attempt to definitively diagnose an intraabdominal malignancy by biopsy can contaminate the abdominal wall by cancerous cells. With follow-up these entrapped [...]]]></description>
			<content:encoded><![CDATA[<p><em>Tumori</em>. 2008 May-Jun;94(3):309-13.[<a href="http://www.ncbi.nlm.nih.gov/pubmed/18705396?dopt=AbstractPlus" target="_blank">Link</a>]</p>
<p><strong>  Yan T, Sugarbaker P.</strong></p>
<p> Peritoneal Surface Malignancy Program, Washington Cancer Institute, Washington Hospital Center, Washington, DC 20010, USA.</p>
<h3 class="abstract">Abstract</h3>
<p> <strong>Aims and Background</strong>: Diagnostic technologies which penetrate the abdominal wall in an attempt to definitively diagnose an intraabdominal malignancy by biopsy can contaminate the abdominal wall by cancerous cells. With follow-up these entrapped cancer cells may progress as an abdominal wall recurrence of the disease process. Frequently, laparoscopy is the definitive diagnostic study which results in the abdominal wall cancer progression. </p>
<p><strong>Methods</strong>: We examined recurrences within the abdominal wall and attempted to establish a surgical approach to this problem which would maximize a functional result and minimize the incidence of disease persistence within the abdominal wall.</p>
<p> <strong>Results</strong>: Eighteen patients with abdominal wall recurrence were studied. Laparoscopy port sites resulted in the abdominal wall disease in eight patients, in four the recurrence was at a previous ostomy site, in three it was in a Pfannenstiel incision and in three it was in a McBurney incision site. All of these patients were treated by total resection of the rectus abdominis muscle. This resulted in a complete removal of visible disease that was dissecting along the fibers of the rectus abdominis muscle. </p>
<p><strong>Conclusions</strong>: No patients required reoperation for abdominal wall hernia and mesh repair was not used in any of these patients. Disease control within the abdominal wall has been excellent.</p>
<h3 class="glossary">Glossary</h3><dl class="glossary"><dt>resection</dt><dd> surgery to remove part or all of an organ or other structure.</dd><dt>recurrence</dt><dd> cancer that has come back after treatment. Local recurrence is when the cancer comes back at the same place as the original cancer. Regional recurrence is when the cancer appears in the lymph nodes near the first site. Distant recurrence is when it appears in organs or tissues (such as the lungs, liver, bone marrow, or brain) farther from the original site than the regional lymph nodes. Metastasis means that the disease has recurred at a distant site.</dd><dt>ostomy</dt><dd><span class="pronunciation">(os-to-me)</span> a general term meaning an opening, especially one made by surgery. See also colostomy, ileostomy, urostomy, and tracheostomy.</dd><dt>cancer</dt><dd>malignancy; a group of diseases typified by abnormal, generally out-of-control, cell growth.</dd><dt>biopsy</dt><dd><span class="pronunciation">(buy-op-see)</span> the removal of a sample of tissue to see whether cancer cells are present. There are several kinds of biopsies. In some, a very thin needle is used to draw fluid and cells from a lump. In a core biopsy, a larger needle is used to remove more tissue.</dd><dt>peritoneal</dt><dd><span class="pronunciation">(pair-uh-tuh-nee-al)</span> the serous membrane that lines the cavity of the abdomen. (More on <a href="http://www.mesotheliomacenter.org/about/peritoneal-mesothelioma.php" target="_blank" title="(opens in a new window.)">Peritoneal Mesothelioma</a>.)  </dd></dl>]]></content:encoded>
			<wfw:commentRss>http://www.mesothelioma-line.com/articles/2008/08/19/rectus-abdominis-muscle-resection-for-abdominal-wall-recurrence-of-mucinous-adenocarcinoma-or-peritoneal-mesothelioma/feed/</wfw:commentRss>
		</item>
		<item>
		<title>Mesothelioma Epidemiology, Carcinogenesis, and Pathogenesis</title>
		<link>http://www.mesothelioma-line.com/articles/2008/08/19/mesothelioma-epidemiology-carcinogenesis-and-pathogenesis/</link>
		<comments>http://www.mesothelioma-line.com/articles/2008/08/19/mesothelioma-epidemiology-carcinogenesis-and-pathogenesis/#comments</comments>
		<pubDate>Tue, 19 Aug 2008 19:50:29 +0000</pubDate>
		<dc:creator>Administrator</dc:creator>
		
		<category><![CDATA[Causation]]></category>

		<category><![CDATA[Epidemiological]]></category>

		<category><![CDATA[Full Archive]]></category>

		<category><![CDATA[General]]></category>

		<category><![CDATA[Occupational Asbestos Exposure]]></category>

		<category><![CDATA[SV40]]></category>

		<category><![CDATA[Type of Assessment:]]></category>

		<guid isPermaLink="false">http://www.mesothelioma-line.com/articles/?p=1314</guid>
		<description><![CDATA[Current Treatment Options in Oncology. 2008 Aug 15. [Epub ahead of print] [Link]
Yang H, Testa JR, Carbone M.
Cancer Research Center of Hawaii, University of Hawaii, Honolulu, HI, 96813, USA.
Abstract
Opinion Statement: The incidence of mesothelioma has gone from almost none to the current 2500-3000 cases per year in the USA. This estimate is an extrapolation based [...]]]></description>
			<content:encoded><![CDATA[<p><em>Current Treatment Options in Oncology</em>. 2008 Aug 15. [Epub ahead of print] [<a href="http://www.springerlink.com/content/765518k881325327/" target="_blank">Link</a>]</p>
<p><strong>Yang H, Testa JR, Carbone M.</strong></p>
<p>Cancer Research Center of Hawaii, University of Hawaii, Honolulu, HI, 96813, USA.</p>
<h3 class="abstract">Abstract</h3>
<p><strong>Opinion Statement</strong>: The incidence of mesothelioma has gone from almost none to the current 2500-3000 cases per year in the USA. This estimate is an extrapolation based on information available from the Surveillance, Epidemiology and End Results (SEER) Program that collects information on approximately 12% of the US population. Mesothelioma is a cancer that is linked to exposure to carcinogenic mineral fibers. Asbestos and erionite have a proven causative role; the possible role of other mineral fibers in causing mesothelioma is being investigated. Asbestos is considered the main cause of mesothelioma in the US and in the Western world. The capacity of asbestos to induce mesothelioma has been linked to its ability to cause the release of TNF-alpha (that promotes mesothelial cells survival), other cytokines and growth factors, and of mutagenic oxygen radicals from exposed mesothelial cells and nearby macrophages. Some investigators proposed that as a consequence of the regulations to prevent exposure and to forbid and/or limit the use of asbestos, the incidence of mesothelioma in the US (and in some European countries) should have started to decline before or around the year 2000, and sharply decline thereafter. Unfortunately, there are no data available yet to support this optimistic hypothesis. Simian virus 40 (SV40) infection and radiation exposure are additional causes, although their contribution to the overall incidence of mesothelioma is unknown. Recent data from several laboratories indicate that asbestos exposure and SV40 infection are co-carcinogens in causing mesothelioma in rodents and in causing malignant transformation of human mesothelial cells in tissue culture. An exciting new development comes from the discovery that genetic susceptibility to mineral fiber carcinogenesis plays a critical role in the incidence of this cancer in certain families. It is hoped that the identification of this putative mesothelioma gene will lead to novel mechanistically driven preventive and therapeutic approaches.</p>
<h3 class="glossary">Glossary</h3><dl class="glossary"><dt>oncology</dt><dd><span class="pronunciation">(on-call-o-jee)</span> the branch of medicine concerned with the diagnosis and treatment of cancer.</dd><dt>growth factors</dt><dd> a naturally occurring protein that causes cells to grow and divide. Too much growth factor production by some cancer cells helps them grow quickly, and new treatments to block these growth factors are being tested in clinical trials. Other growth factors help normal cells recover from side effects of chemotherapy.</dd><dt>gene</dt><dd> a segment of DNA that contains information on hereditary characteristics such as hair color, eye color, and height, as well as susceptibility to certain diseases. Women who have BRCA1 or BRCA2 gene mutations (defects) have an inherited tendency to develop breast cancer.</dd><dt>epidemiology</dt><dd><span class="pronunciation">(ep-uh-deem-ee-AHL-uh-gee)</span> the study of diseases in populations by collecting and analyzing statistical data. In the field of cancer, epidemiologists look at how many people have cancer; who gets specific types of cancer; and what factors (such as environment, job hazards, family patterns, and personal habits, such as smoking and diet) play a part in the development of cancer.</dd><dt>cancer</dt><dd>malignancy; a group of diseases typified by abnormal, generally out-of-control, cell growth.</dd><dt>tissue</dt><dd> a collection of cells, united to perform a particular function.</dd><dt>virus</dt><dd> very small organisms that cause infections. Viruses are too small to be seen with a regular microscope. They reproduce only in living cells.</dd><dt>mesothelioma</dt><dd>a tumor derived from mesothelial tissue, such as the peritoneum (lining the abdomen) or pleura (lining the lungs). More on <a href="http://www.mesotheliomacenter.org/">mesothelioma</a>. </dd></dl>]]></content:encoded>
			<wfw:commentRss>http://www.mesothelioma-line.com/articles/2008/08/19/mesothelioma-epidemiology-carcinogenesis-and-pathogenesis/feed/</wfw:commentRss>
		</item>
		<item>
		<title>National Mesothelioma Virtual Bank: a standard based biospecimen and clinical data resource to enhance translational research</title>
		<link>http://www.mesothelioma-line.com/articles/2008/08/14/national-mesothelioma-virtual-bank-a-standard-based-biospecimen-and-clinical-data-resource-to-enhance-translational-research/</link>
		<comments>http://www.mesothelioma-line.com/articles/2008/08/14/national-mesothelioma-virtual-bank-a-standard-based-biospecimen-and-clinical-data-resource-to-enhance-translational-research/#comments</comments>
		<pubDate>Thu, 14 Aug 2008 19:46:47 +0000</pubDate>
		<dc:creator>Administrator</dc:creator>
		
		<category><![CDATA[Epidemiological]]></category>

		<category><![CDATA[Full Archive]]></category>

		<category><![CDATA[General]]></category>

		<category><![CDATA[Type of Assessment:]]></category>

		<guid isPermaLink="false">http://www.mesothelioma-line.com/articles/?p=1312</guid>
		<description><![CDATA[BMC Cancer. 2008 Aug 13;8(1):236. [Epub ahead of print] [Link]
Amin W, Parwani AV, Schmandt L, Mohanty SK, Farhat G, Pople AK, Winters SB, Whelan NB, Schneider AM, Milnes JT, Valdivieso FA, Feldman M, Pass HI, Dhir R, Melamed J, Becich MJ.
Abstract
Background: Advances in translational research have led to the need for well characterized biospecimens for [...]]]></description>
			<content:encoded><![CDATA[<p><em>BMC Cancer</em>. 2008 Aug 13;8(1):236. [Epub ahead of print] [<a href="http://www.biomedcentral.com/1471-2407/8/236" target="_blank">Link</a>]</p>
<p><strong>Amin W, Parwani AV, Schmandt L, Mohanty SK, Farhat G, Pople AK, Winters SB, Whelan NB, Schneider AM, Milnes JT, Valdivieso FA, Feldman M, Pass HI, Dhir R, Melamed J, Becich MJ.</strong></p>
<h3 class="abstract">Abstract</h3>
<p><strong>Background</strong>: Advances in translational research have led to the need for well characterized biospecimens for research. The National Mesothelioma Virtual Bank (NMVB) is an initiative which collects annotated datasets relevant to human mesothelioma to develop an enterprise biospecimen resource to fulfill researchers&#8217; need.</p>
<p><strong>Methods</strong>: The NMVB architecture is based on three major components: (a) common data elements (based on CAP protocol and NAACCR standards), (b) clinical and epidemiologic data annotation, and (c) data query tools. These tools work interoperably to standardize the entire process of annotation. The NMVB tool is based upon the caTISSUE Clinical Annotation Engine (CAE), developed by the University of Pittsburgh in cooperation with the Cancer Biomedical Informatics GridTM (caBIGTM, see http://cabig.nci.nih.gov). This application provides a web-based system for annotating, importing and searching mesothelioma cases. The underlying information model is constructed utilizing Unified Modeling Language (UML) class diagrams, hierarchical relationships and Enterprise Architect (EA) software. Result: The database provides researchers real-time access to richly annotated specimens and integral information related to mesothelioma. The data disclosed are tightly regulated depending upon users&#8217; authorization and depending on the participating institute that is amenable to the local IRB and regulation committee reviews.</p>
<p><strong>Conclusion</strong>: The NMVB currently has over 600 annotated cases available for researchers that include paraffin embedded tissues, tissue microarrays, serum and genomic DNA. The NMVB is a virtual biospecimen registry with robust translational biomedical informatics support to facilitate basic science, clinical, and translational research. Furthermore, it protects patient privacy by disclosing only de-identified datasets to assure that biospecimens can be made accessible to researchers.</p>
<h3 class="glossary">Glossary</h3><dl class="glossary"><dt>protocol</dt><dd><span class="pronunciation">(pro-teh-call)</span> a formal outline or plan, such as a description of what treatments a patient will receive and exactly when each should be given.</dd><dt>DNA</dt><dd><span class="pronunciation">(dee-ok-see-ri-bo-new-CLAY-ic)</span> abbreviation for deoxyribonucleic acid. DNA holds genetic information on cell growth, division, and function.</dd><dt>cancer</dt><dd>malignancy; a group of diseases typified by abnormal, generally out-of-control, cell growth.</dd><dt>tissue</dt><dd> a collection of cells, united to perform a particular function.</dd><dt>mesothelioma</dt><dd>a tumor derived from mesothelial tissue, such as the peritoneum (lining the abdomen) or pleura (lining the lungs). More on <a href="http://www.mesotheliomacenter.org/">mesothelioma</a>. </dd></dl>]]></content:encoded>
			<wfw:commentRss>http://www.mesothelioma-line.com/articles/2008/08/14/national-mesothelioma-virtual-bank-a-standard-based-biospecimen-and-clinical-data-resource-to-enhance-translational-research/feed/</wfw:commentRss>
		</item>
		<item>
		<title>Soft tissue sarcoma metastatic to pleura</title>
		<link>http://www.mesothelioma-line.com/articles/2008/08/14/soft-tissue-sarcoma-metastatic-to-pleura/</link>
		<comments>http://www.mesothelioma-line.com/articles/2008/08/14/soft-tissue-sarcoma-metastatic-to-pleura/#comments</comments>
		<pubDate>Thu, 14 Aug 2008 19:44:09 +0000</pubDate>
		<dc:creator>Administrator</dc:creator>
		
		<category><![CDATA[Diagnosis &#038; Differentiation]]></category>

		<category><![CDATA[Full Archive]]></category>

		<category><![CDATA[Pleural]]></category>

		<category><![CDATA[Pleural Biopsy]]></category>

		<category><![CDATA[Sarcomatoid]]></category>

		<category><![CDATA[Type of Assessment:]]></category>

		<category><![CDATA[Type of Mesothelioma:]]></category>

		<category><![CDATA[thoracoscopy]]></category>

		<guid isPermaLink="false">http://www.mesothelioma-line.com/articles/?p=1310</guid>
		<description><![CDATA[Tuberkuloz ve Toraks. 2008 Apr;56(2):197-200. [Link]
Yildirim H, Metıntaş M, Ak G, Dündar E, Ergınel S.
Department of Chest Diseases, Faculty of Medicine, Osmangazi University, Eskişehir, Turkey. heylul2002@yahoo.com.
Abstract
Almost all cancers can cause distant pleural metastases. However, pleural metastases of soft tissue sarcoma that constitute less than 1% of adult solid malignancy are extremely rare. It is very [...]]]></description>
			<content:encoded><![CDATA[<p><em>Tuberkuloz ve Toraks</em>. 2008 Apr;56(2):197-200. [<a href="http://www.journalagent.com/pubmed/linkout.asp?ISSN=0494-1373&amp;PMID=18701980" target="_blank">Link</a>]</p>
<p><strong>Yildirim H, Metıntaş M, Ak G, Dündar E, Ergınel S.</strong></p>
<p>Department of Chest Diseases, Faculty of Medicine, Osmangazi University, Eskişehir, Turkey. heylul2002@yahoo.com.</p>
<h3 class="abstract">Abstract</h3>
<p>Almost all cancers can cause distant pleural metastases. However, pleural metastases of soft tissue sarcoma that constitute less than 1% of adult solid malignancy are extremely rare. It is very difficult to distinguish them form sarcomatous malignant mesothelioma on histopathological features. We report a 57 year-old man who presented to us with left chest pain and progressive dyspnea and was diagnosed to have a pleural metastases of soft tissue sarcoma by thoracoscopic biopsy.</p>
<h3 class="glossary">Glossary</h3><dl class="glossary"><dt>sarcoma</dt><dd><span class="pronunciation">(sar-co-muh)</span> a malignant tumor growing from connective tissues, such as cartilage, fat, muscle, or bone.</dd><dt>biopsy</dt><dd><span class="pronunciation">(buy-op-see)</span> the removal of a sample of tissue to see whether cancer cells are present. There are several kinds of biopsies. In some, a very thin needle is used to draw fluid and cells from a lump. In a core biopsy, a larger needle is used to remove more tissue.</dd><dt>tissue</dt><dd> a collection of cells, united to perform a particular function.</dd><dt>mesothelioma</dt><dd>a tumor derived from mesothelial tissue, such as the peritoneum (lining the abdomen) or pleura (lining the lungs). More on <a href="http://www.mesotheliomacenter.org/">mesothelioma</a>. </dd></dl>]]></content:encoded>
			<wfw:commentRss>http://www.mesothelioma-line.com/articles/2008/08/14/soft-tissue-sarcoma-metastatic-to-pleura/feed/</wfw:commentRss>
		</item>
		<item>
		<title>Full-thickness pleural biopsy using an Insulation-tipped Diathermic knife in a patient with malignant pleural mesothelioma</title>
		<link>http://www.mesothelioma-line.com/articles/2008/08/14/full-thickness-pleural-biopsy-using-an-insulation-tipped-diathermic-knife-in-a-patient-with-malignant-pleural-mesothelioma/</link>
		<comments>http://www.mesothelioma-line.com/articles/2008/08/14/full-thickness-pleural-biopsy-using-an-insulation-tipped-diathermic-knife-in-a-patient-with-malignant-pleural-mesothelioma/#comments</comments>
		<pubDate>Thu, 14 Aug 2008 19:41:38 +0000</pubDate>
		<dc:creator>Administrator</dc:creator>
		
		<category><![CDATA[Case Study]]></category>

		<category><![CDATA[Diagnosis &#038; Differentiation]]></category>

		<category><![CDATA[Full Archive]]></category>

		<category><![CDATA[Pleural Biopsy]]></category>

		<category><![CDATA[Type of Assessment:]]></category>

		<category><![CDATA[thoracoscopy]]></category>

		<guid isPermaLink="false">http://www.mesothelioma-line.com/articles/?p=1308</guid>
		<description><![CDATA[Kyobu Geka. 2008 Aug;61(9):769-73. [Link]
Sasada S, Kawahara K, Okamoto N, Kobayashi M, Iwasaki T, Michida T, Suzuki H, Hirashima T, Matsu K, Ohta M, Ishida A, Miyazawa T.
Department of Thoracic Malignancy, Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, Habikino, Japan.
Abstract
A 72-year-old woman was pointed out a right pleural effusion and thickening pleura on [...]]]></description>
			<content:encoded><![CDATA[<p><em>Kyobu Geka</em>. 2008 Aug;61(9):769-73. [<a href="http://www.ncbi.nlm.nih.gov/pubmed/18697458?dopt=AbstractPlus" target="_blank">Link</a>]</p>
<p><strong>Sasada S, Kawahara K, Okamoto N, Kobayashi M, Iwasaki T, Michida T, Suzuki H, Hirashima T, Matsu K, Ohta M, Ishida A, Miyazawa T.</strong></p>
<p>Department of Thoracic Malignancy, Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, Habikino, Japan.</p>
<h3 class="abstract">Abstract</h3>
<p>A 72-year-old woman was pointed out a right pleural effusion and thickening pleura on the chest computed tomography. The patient underwent semiflexible thoracoscopy under local anesthesia at the endoscopy room. The patient was placed in the lateral decubitus position, and flexible trocar was inserted with the single puncture technique. At the macroscopic findings, the parietal pleura were thickened prominently, and patchy plaques were occasionally recognized. A standard biopsy forceps hardly grasped pleura because of presence of scar, so we performed pleural biopsy using Insulation-tipped Diathermic (IT) knife. A subpleural injection of saline containing 0.5% lidokine and 0.005% epinephrine was performed for raising the affected parietal pleura with an injection needle. After a pin hole was made, the pleural lesion was incised in a circle by manipulating the IT knife, and the incised pleura were removed. Pathology revealed extensive fibrosis and epithelial mesothelioma by the<br />
specimen. This biopsy technique using IT knife through semiflexible thoracoscopy enabled to obtain a full-thickness pleura It is thought to be useful for the diagnosis of malignant pleural mesothelioma (MPM) in which standard forceps are difficult to grasp.</p>
<h3 class="glossary">Glossary</h3><dl class="glossary"><dt>pleura</dt><dd><span class="pronunciation">(pler-uh)</span> the membrane around the lungs and lining of the chest cavity. (<a href="http://www.mesotheliomacenter.org/about/pleural-mesothelioma.php" target="_blank" title="(opens in a new window.)">Pleural mesothelioma</a>.)  </dd><dt>lesion</dt><dd><span class="pronunciation">(lee-zhun)</span> a change in body tissue; sometimes used as another word for tumor.</dd><dt>fibrosis</dt><dd> formation of scar-like (fibrous) tissue. This can occur anywhere in the body.</dd><dt>endoscopy</dt><dd><span class="pronunciation">(en-dos-ko-pee)</span> inspection of body organs or cavities using a flexible, lighted tube called an endoscope.</dd><dt>diagnosis</dt><dd> identifying a disease by its signs or symptoms, and by using imaging procedures and laboratory findings. The earlier a diagnosis of cancer is made, the better the chance for long-term survival.</dd><dt>biopsy</dt><dd><span class="pronunciation">(buy-op-see)</span> the removal of a sample of tissue to see whether cancer cells are present. There are several kinds of biopsies. In some, a very thin needle is used to draw fluid and cells from a lump. In a core biopsy, a larger needle is used to remove more tissue.</dd><dt>anesthesia</dt><dd><span class="pronunciation">(an-es-thee-zha)</span> the loss of feeling or sensation as a result of drugs or gases. General anesthesia causes loss of consciousness (&quot;puts you to sleep&quot;). Local or regional anesthesia numbs only a certain area.</dd><dt>mesothelioma</dt><dd>a tumor derived from mesothelial tissue, such as the peritoneum (lining the abdomen) or pleura (lining the lungs). More on <a href="http://www.mesotheliomacenter.org/">mesothelioma</a>. </dd><dt>pleural effusion</dt><dd>an abnormal accumulation of fluid, usually caused by trauma or disease, in the pleural space.</dd></dl>]]></content:encoded>
			<wfw:commentRss>http://www.mesothelioma-line.com/articles/2008/08/14/full-thickness-pleural-biopsy-using-an-insulation-tipped-diathermic-knife-in-a-patient-with-malignant-pleural-mesothelioma/feed/</wfw:commentRss>
		</item>
		<item>
		<title>Enhanced antitumor therapy by inhibition of p21waf1 in human malignant mesothelioma</title>
		<link>http://www.mesothelioma-line.com/articles/2008/08/14/enhanced-antitumor-therapy-by-inhibition-of-p21waf1-in-human-malignant-mesothelioma/</link>
		<comments>http://www.mesothelioma-line.com/articles/2008/08/14/enhanced-antitumor-therapy-by-inhibition-of-p21waf1-in-human-malignant-mesothelioma/#comments</comments>
		<pubDate>Thu, 14 Aug 2008 19:34:16 +0000</pubDate>
		<dc:creator>Administrator</dc:creator>
		
		<category><![CDATA[Full Archive]]></category>

		<category><![CDATA[Immune-based Therapies]]></category>

		<category><![CDATA[Kinase Inhibitors]]></category>

		<category><![CDATA[New &#038; Novel]]></category>

		<category><![CDATA[Treatment]]></category>

		<category><![CDATA[Type of Assessment:]]></category>

		<guid isPermaLink="false">http://www.mesothelioma-line.com/articles/?p=1306</guid>
		<description><![CDATA[Clinical Cancer Research. 2008 Aug 15;14(16):5099-107. [Link]
 Lazzarini R, Moretti S, Orecchia S, Betta PG, Procopio A, Catalano A.
 Department of Molecular Pathology and Innovative Therapies, Marche University, Ancona, Italy.
Abstract
Purpose: The p21 cyclin-dependent kinase inhibitor was frequently expressed in human malignant pleural mesothelioma (MPM) tissues as well as cell lines. Recent data indicate that p21 [...]]]></description>
			<content:encoded><![CDATA[<p><em>Clinical Cancer Research</em>. 2008 Aug 15;14(16):5099-107. [<a href="http://clincancerres.aacrjournals.org/cgi/content/abstract/14/16/5099" target="_blank">Link</a>]</p>
<p><strong> Lazzarini R, Moretti S, Orecchia S, Betta PG, Procopio A, Catalano A.</strong></p>
<p> Department of Molecular Pathology and Innovative Therapies, Marche University, Ancona, Italy.</p>
<h3 class="abstract">Abstract</h3>
<p><strong>Purpose:</strong> The p21 cyclin-dependent kinase inhibitor was frequently expressed in human malignant pleural mesothelioma (MPM) tissues as well as cell lines. Recent data indicate that p21 keeps tumor cells alive after DNA damage, favoring a survival advantage. In this study, we assessed the possibility of p21 suppression as a therapeutic target for MPM.</p>
<p><P> <strong>Experimental Design:</strong> We established two different MPM-derived (from H28 and H2052 cells) subclones using vector-based short hairpin RNA (shRNA). Then, chemosensitivity against low doses of antineoplastic DNA-damaging agents was investigated by colony formation assays, and furthermore, the type of cell response induced by these drugs was analyzed. To examine the effect of p21 shRNA on chemosensitivity <I>in vivo</I>, tumor formation assays in nude mice were done.</P><br />
<P> <strong>Results:</strong> In colony formation assay, the IC<sub>50</sub> of doxorubicin was 33 &#177; 3.0 nmol/L in p21 shRNA-transfected cells with respect to 125 &#177; 10 nmol/L of control vector&#8211;transfected cells. This enhancement of growth inhibition was achieved by converting a senescence-like growth arrest to apoptosis in response to doxorubicin, etoposide, and CPT11. In the <I>in vivo</I> assays, CPT11 and loss-of-expression of p21 in combination led to considerable suppression of tumor growth associated with a substantially enhanced apoptotic response, whereas CPT11 alone was ineffective at inducing these responses.</P><br />
<P> <strong>Conclusions:</strong> These results indicated that p21 might play an important role in chemosensitivity to anticancer agents, and the suppression of its expression might be a potential therapeutic target for MPM.</P></p>
<h3 class="glossary">Glossary</h3><dl class="glossary"><dt>DNA</dt><dd><span class="pronunciation">(dee-ok-see-ri-bo-new-CLAY-ic)</span> abbreviation for deoxyribonucleic acid. DNA holds genetic information on cell growth, division, and function.</dd><dt>cell</dt><dd>the basic unit of which all living things are made. Cells replace themselves by splitting and forming new cells (mitosis). The processes that control the formation of new cells and the death of old cells are disrupted in cancer.</dd><dt>cancer</dt><dd>malignancy; a group of diseases typified by abnormal, generally out-of-control, cell growth.</dd><dt>tumor</dt><dd> an abnormal lump or mass of tissue. Tumors can be benign (not cancerous) or malignant (cancerous).</dd><dt>mesothelioma</dt><dd>a tumor derived from mesothelial tissue, such as the peritoneum (lining the abdomen) or pleura (lining the lungs). More on <a href="http://www.mesotheliomacenter.org/">mesothelioma</a>. </dd><dt>apoptosis</dt><dd>a type of cell death in which the cell basically commits suicide; scientists believe some types of cancer may originate from an interruption of this programmed cell death, allowing cells to grow out of control.</dd></dl>]]></content:encoded>
			<wfw:commentRss>http://www.mesothelioma-line.com/articles/2008/08/14/enhanced-antitumor-therapy-by-inhibition-of-p21waf1-in-human-malignant-mesothelioma/feed/</wfw:commentRss>
		</item>
		<item>
		<title>Acute generalized exanthematous pustulosis after pemetrexed, and recurrence after re-introduction</title>
		<link>http://www.mesothelioma-line.com/articles/2008/08/14/acute-generalized-exanthematous-pustulosis-after-pemetrexed-and-recurrence-after-re-introduction/</link>
		<comments>http://www.mesothelioma-line.com/articles/2008/08/14/acute-generalized-exanthematous-pustulosis-after-pemetrexed-and-recurrence-after-re-introduction/#comments</comments>
		<pubDate>Thu, 14 Aug 2008 19:24:32 +0000</pubDate>
		<dc:creator>Administrator</dc:creator>
		
		<category><![CDATA[Chemotherapy]]></category>

		<category><![CDATA[Full Archive]]></category>

		<category><![CDATA[Pemetrexed (Alimta)]]></category>

		<category><![CDATA[Treatment]]></category>

		<category><![CDATA[Type of Assessment:]]></category>

		<guid isPermaLink="false">http://www.mesothelioma-line.com/articles/?p=1304</guid>
		<description><![CDATA[Clinical and Experimental Dermatology. 2008 Aug 9. [Epub ahead of print] [Link]
Bracke A, Van Marck E, Lambert J.
University Hospital Antwerp, Antwerp, Belgium.
Abstract
Acute generalized exanthematous pustulosis (AGEP) is a rare cutaneous reaction, which in most cases, is related to medication. Pemetrexed is an antifolate drug, approved for treatment of metastatic non-small-cell lung cancer (NSCLC) and malignant [...]]]></description>
			<content:encoded><![CDATA[<p><em>Clinical and Experimental Dermatology</em>. 2008 Aug 9. [Epub ahead of print] [<a href="http://www3.interscience.wiley.com/journal/121375900/abstract?CRETRY=1&amp;SRETRY=0" target="_blank">Link</a>]</p>
<p><strong>Bracke A, Van Marck E, Lambert J.</strong></p>
<p>University Hospital Antwerp, Antwerp, Belgium.</p>
<h3 class="abstract">Abstract</h3>
<p>Acute generalized exanthematous pustulosis (AGEP) is a rare cutaneous reaction, which in most cases, is related to medication. Pemetrexed is an antifolate drug, approved for treatment of metastatic non-small-cell lung cancer (NSCLC) and malignant pleural mesothelioma (MPM). We present a case of AGEP caused by pemetrexed, and a recurrence of this eruption after re-introduction of pemetrexed despite use of corticosteroids.</p>
<h3 class="glossary">Glossary</h3><dl class="glossary"><dt>recurrence</dt><dd> cancer that has come back after treatment. Local recurrence is when the cancer comes back at the same place as the original cancer. Regional recurrence is when the cancer appears in the lymph nodes near the first site. Distant recurrence is when it appears in organs or tissues (such as the lungs, liver, bone marrow, or brain) farther from the original site than the regional lymph nodes. Metastasis means that the disease has recurred at a distant site.</dd><dt>cell</dt><dd>the basic unit of which all living things are made. Cells replace themselves by splitting and forming new cells (mitosis). The processes that control the formation of new cells and the death of old cells are disrupted in cancer.</dd><dt>cancer</dt><dd>malignancy; a group of diseases typified by abnormal, generally out-of-control, cell growth.</dd><dt>mesothelioma</dt><dd>a tumor derived from mesothelial tissue, such as the peritoneum (lining the abdomen) or pleura (lining the lungs). More on <a href="http://www.mesotheliomacenter.org/">mesothelioma</a>. </dd><dt>pemetrexed</dt><dd>chemotheraputic agent that interferes with a crucial process that allows cancer cells to reproduce and spread. Specifically, pemetrexed stops the production of three enzymes that are required to feed the cancer cell. Often used in combination with cisplatin. Marketed under the name ALIMTA. See: <a href="/articles/glossary/?id=5">Alimta</a>. </dd></dl>]]></content:encoded>
			<wfw:commentRss>http://www.mesothelioma-line.com/articles/2008/08/14/acute-generalized-exanthematous-pustulosis-after-pemetrexed-and-recurrence-after-re-introduction/feed/</wfw:commentRss>
		</item>
		<item>
		<title>Malignant mesothelioma in garment sewing-machine workers</title>
		<link>http://www.mesothelioma-line.com/articles/2008/08/12/malignant-mesothelioma-in-garment-sewing-machine-workers/</link>
		<comments>http://www.mesothelioma-line.com/articles/2008/08/12/malignant-mesothelioma-in-garment-sewing-machine-workers/#comments</comments>
		<pubDate>Tue, 12 Aug 2008 19:21:23 +0000</pubDate>
		<dc:creator>Administrator</dc:creator>
		
		<category><![CDATA[Causation]]></category>

		<category><![CDATA[Epidemiological]]></category>

		<category><![CDATA[Full Archive]]></category>

		<category><![CDATA[Occupational Asbestos Exposure]]></category>

		<category><![CDATA[Type of Assessment:]]></category>

		<guid isPermaLink="false">http://www.mesothelioma-line.com/articles/?p=1302</guid>
		<description><![CDATA[La Medicina del Lavoro. 2008 May-Jun;99(3):187-93. [Link]
 Barbieri PG, Somigliana A, Girelli R, Lombardi S, Festa R, Silvestri S.
 Servizio Prevenzione e Sicurezza Ambienti di Lavoro, ASL Brescia. pietro.barbieri@aslbrescia.it
Abstract
 Background: Due to poor information collected through patient interviews, a considerable number of malignant mesothelioma (MM) cases still remain classified as &#34;unknown&#34; asbestos exposure in the [...]]]></description>
			<content:encoded><![CDATA[<p><em>La Medicina del Lavoro</em>. 2008 May-Jun;99(3):187-93. [<a href="http://www.ncbi.nlm.nih.gov/pubmed/18689090?dopt=AbstractPlus" target="_blank">Link</a>]</p>
<p> <strong>Barbieri PG, Somigliana A, Girelli R, Lombardi S, Festa R, Silvestri S.</strong></p>
<p> Servizio Prevenzione e Sicurezza Ambienti di Lavoro, ASL Brescia. pietro.barbieri@aslbrescia.it</p>
<h3 class="abstract">Abstract</h3>
<p> <strong>Background</strong>: Due to poor information collected through patient interviews, a considerable number of malignant mesothelioma (MM) cases still remain classified as &quot;unknown&quot; asbestos exposure in the Italian Mesotelioma Registry (Re.Na.M). At the same time, some occupational asbestos exposures, which were previously unknown, have been demonstrated in certain types of work, i.e., in agriculture and in the textile industry. </p>
<p><strong>Objectives</strong>: The aim of this research was to investigate the possible past occupational exposure to asbestos in clothing workers using sewing-machines. </p>
<p><strong>Methods</strong>: The MM cases were collected from the Mesothelioma Registry of Brescia. Work histories were obtained via a standardized questionnaire. Investigations were conducted in sewing-machine maintenance workshop in order to collect information regarding the possible use of asbestos parts. In addition, the use of asbestos friction materials and the use of insulated asbestos materials was checked in the clothing divisions by interviewing the management and maintenance workers of two companies where cases of MM were observed. </p>
<p><strong>Results</strong>: The Mesothelioma Registry of Brescia identified and collected 10 MM cases with past work in the clothing industry: 6 used sewing-machines and 4 were self-employed tailors. The search for asbestos materials gave positive results as the use of friction materials had been widespread since the 1950&#8217;s in all types of sewing-machines; in addition, asbestos materials were used to insulate some parts of the ironing equipment and the steam pipelines. </p>
<p><strong>Conclusion</strong>: The results of this investigation suggest assigning at least &quot;possible occupational asbestos exposure&quot; to those cases employed in clothing manufacture since the 1950&#8217;s, who used sewing-machines or pressing machines, according to the Re.Na.M guidelines. Other possible occupational exposures to asbestos in this working sector cannot be excluded; when the simple interview of patients does not reveal such exposures further investigations are needed in order to demonstrate all the possible circumstances of exposure.</p>
<h3 class="glossary">Glossary</h3><dl class="glossary"><dt>mesothelioma</dt><dd>a tumor derived from mesothelial tissue, such as the peritoneum (lining the abdomen) or pleura (lining the lungs). More on <a href="http://www.mesotheliomacenter.org/">mesothelioma</a>. </dd></dl>]]></content:encoded>
			<wfw:commentRss>http://www.mesothelioma-line.com/articles/2008/08/12/malignant-mesothelioma-in-garment-sewing-machine-workers/feed/</wfw:commentRss>
		</item>
		<item>
		<title>Clinical Activity of Vinflunine in Transitional Cell Carcinoma of the Urothelium and Other Solid Tumors</title>
		<link>http://www.mesothelioma-line.com/articles/2008/08/09/clinical-activity-of-vinflunine-in-transitional-cell-carcinoma-of-the-urothelium-and-other-solid-tumors/</link>
		<comments>http://www.mesothelioma-line.com/articles/2008/08/09/clinical-activity-of-vinflunine-in-transitional-cell-carcinoma-of-the-urothelium-and-other-solid-tumors/#comments</comments>
		<pubDate>Sat, 09 Aug 2008 15:20:32 +0000</pubDate>
		<dc:creator>Administrator</dc:creator>
		
		<category><![CDATA[Full Archive]]></category>

		<category><![CDATA[New &#038; Novel]]></category>

		<category><![CDATA[Treatment]]></category>

		<category><![CDATA[Type of Assessment:]]></category>

		<guid isPermaLink="false">http://www.mesothelioma-line.com/articles/?p=1301</guid>
		<description><![CDATA[Bellmunt J, Delgado FM, George C.
Medical Oncology Service, University Hospital Del Mar, Paseo Maritimo 25-29, Barcelona, Spain. jbellmunt@imas.imim.es
Abstract
Vinflunine is a novel microtubule inhibitor of the vinca alkaloid class currently in development for the treatment of advanced transitional cell carcinoma of the urothelium (TCCU) and other solid tumors. This review summarizes the clinical activity of vinflunine [...]]]></description>
			<content:encoded><![CDATA[<p><strong>Bellmunt J, Delgado FM, George C.</strong></p>
<p>Medical Oncology Service, University Hospital Del Mar, Paseo Maritimo 25-29, Barcelona, Spain. jbellmunt@imas.imim.es</p>
<h3 class="abstract">Abstract</h3>
<p>Vinflunine is a novel microtubule inhibitor of the vinca alkaloid class currently in development for the treatment of advanced transitional cell carcinoma of the urothelium (TCCU) and other solid tumors. This review summarizes the clinical activity of vinflunine as a single agent or in combination with other antineoplastic drugs. Vinflunine is active against a variety of tumor types, including advanced TCCU, metastatic breast cancer, advanced non-small cell lung cancer, and malignant pleural mesothelioma. It has a manageable and noncumulative toxicity profile, and its specific mechanism of action has been linked to a reduced potential for peripheral sensory neuropathy. The activity and tolerability of this agent warrant further investigation. Phase 3 trials are underway to further define the extent of clinical benefit provided by vinflunine in patients with advanced solid malignancies.</p>
<h3 class="glossary">Glossary</h3><dl class="glossary"><dt>oncology</dt><dd><span class="pronunciation">(on-call-o-jee)</span> the branch of medicine concerned with the diagnosis and treatment of cancer.</dd><dt>cell</dt><dd>the basic unit of which all living things are made. Cells replace themselves by splitting and forming new cells (mitosis). The processes that control the formation of new cells and the death of old cells are disrupted in cancer.</dd><dt>carcinoma</dt><dd><span class="pronunciation">(car-sin-o-ma)</span> a malignant tumor that begins in the lining layer (epithelial cells) of organs. At least 80% of all cancers are carcinomas.</dd><dt>cancer</dt><dd>malignancy; a group of diseases typified by abnormal, generally out-of-control, cell growth.</dd><dt>tumor</dt><dd> an abnormal lump or mass of tissue. Tumors can be benign (not cancerous) or malignant (cancerous).</dd><dt>mesothelioma</dt><dd>a tumor derived from mesothelial tissue, such as the peritoneum (lining the abdomen) or pleura (lining the lungs). More on <a href="http://www.mesotheliomacenter.org/">mesothelioma</a>. </dd></dl>]]></content:encoded>
			<wfw:commentRss>http://www.mesothelioma-line.com/articles/2008/08/09/clinical-activity-of-vinflunine-in-transitional-cell-carcinoma-of-the-urothelium-and-other-solid-tumors/feed/</wfw:commentRss>
		</item>
	</channel>
</rss>
